Conferences

SIU 2021: The Quantified Surgeon: Predicting Patient Outcomes after Robotic Surgery and Automating Skills Assessment

(UroToday.com) In a Hot Topic session during the Société Internationale D’Urologie (SIU) 2021 annual meeting focused on the role of artificial intelligence (AI) in urology, Dr. Andrew Hung assessed the role of AI to predict patient outcomes after robotic surgery and for automating skills assessment.

SIU 2021: 3D Models to Enhance the Quality of Robotic Assisted Partial Nephrectomy

(UroToday.com) In a Hot Topic session of the Société Internationale D’Urologie (SIU) 2021 annual meeting focused on the role of artificial intelligence (AI) in urology, Dr. Jean-Christophe Bernhard discussed the potential of 3-dimensional (3D) models to enhance the quality of robotic-assisted partial nephrectomy.

SIU 2021: The Future of Prostate Cancer Imaging: Will AI Play a Role?

(UroToday.com) In a Hot Topic session of the Société Internationale D’Urologie (SIU) 2021 annual meeting focused on the role of artificial intelligence (AI) in urology, Dr. Mark Emberton discussed the role of AI in prostate cancer imaging. Building on his plenary session talk regarding advances in prostate cancer imaging over the past decade, Dr. Emberton discussed his perspectives on the changing landscape of imaging in the coming decade.

SIU 2021: State-of-the-Art Lecture: Novel Therapies in Renal Cell Carcinoma and the Impact on Surgery

(UroToday.com) In the Plenary session of the Société Internationale D’Urologie (SIU) 2021 annual meeting Dr. Peter Mulders presented a state-of-the-art lecture on novel therapies in renal cell carcinoma (RCC) and the role of nephrectomy in this rapidly evolving treatment landscape.

SIU 2021: Ethical and Legal Considerations of Using Artificial Intelligence in Healthcare

(UroToday.com) In a Hot Topic session during the Société Internationale D’Urologie (SIU) 2021 annual meeting focused on the role of artificial intelligence (AI) in urology, Dr. Quoc-Dien Trinh discussed bias in AI and important ethical and legal considerations in the use of AI in health care.

SIU 2021: Mostafa M. Elhilali Award Lecture: The Butcher, the Baker and the Ice-Cream Maker - A Personal Reflection on Prostate Cancer Treatment over the Last Decade

(UroToday.com) In the Plenary session of the Société Internationale D’Urologie (SIU) 2021 annual meeting, Dr. Mark Emberton presented the SIU-Mostafa M. Elhilali Award Lecture focusing on his reflections on the evolution of prostate cancer treatment.

SIU 2021: DDR Mutations and Response to Chemotherapy 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on biomarkers in cancer and a presentation by Dr. Wassim Kassouf discussing DDR mutations and response to chemotherapy. For context, Dr. Kassouf noted that for metastatic muscle-invasive bladder cancer, 25% of patients do not response to first-line cisplatin-based chemotherapy, and even among responders the majority will subsequently relapse. For patients with localized muscle-invasive disease, neoadjuvant chemotherapy + radical cystectomy is the standard of care, however, the majority of these patients do not benefit from neoadjuvant chemotherapy. Additionally, this is the cohort of patients that may benefit from an assessment of bladder preservation.

SIU 2021: AUA Lecture: 2021 Renal Mass Guideline Update 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a plenary session with the AUA lecture provided by Dr. Sam Chang discussing the 2021 AUA Guideline for renal masses and localized cancer, specifically evaluation, management, and follow-up.1,2 Dr. Chang notes that the AUA guidelines focus on the evaluation and management of clinically localized sporadic renal masses suspicious for renal cell carcinoma (RCC) in adults. This includes solid-enhancing renal tumors and Bosniak 3 and 4 complex cystic renal lesions. Dr. Chang also notes that this guideline addresses the follow-up of renal cancer patients after intervention, including periodic clinical follow-up, abdominal imaging, and chest imaging. The methodology for this guideline is comparable to previous AUA guidelines, as summarized in the following table:

SIU 2021: Immune-related Biomarkers of Bladder Cancer 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on biomarkers in cancer and a presentation by Dr. Murat Bozlu discussing immune-related biomarkers of bladder cancer. Dr. Bozlu started his presentation by noting that bladder cancer makes up 7% of new cancer cases amongst males, accounting for 4% of cancer mortalities. However, screening for bladder cancer in asymptomatic adults is given a grade I recommendation by the USPSTF (neither a recommendation for or against screening), stating that the current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer among asymptomatic adults. Based on clinicopathologic features, the EAU guidelines provide risk group stratification in order to assist with treatment and patient counselling for risk of recurrence and progression:

SIU 2021: Molecular Subtypes of Bladder Cancer 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on biomarkers in cancer and a presentation by Dr. Seth Lerner discussing molecular subtypes of bladder cancer. Dr. Lerner started by highlighting seminal work from his group that used the bladder cancer TCGA dataset to provide a comprehensive molecular characterization of muscle invasive bladder cancer.1 Among 412 muscle-invasive bladder cancer specimens, this work identified five expression subtypes including: luminal, luminal papillary, luminal infiltrated, basal squamous, and neuronal,

SIU 2021: Serum Biomarkers in Invasive Bladder Cancer 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on biomarkers in cancer and a presentation by Dr. Sia Daneshmand discussing serum biomarkers in invasive bladder cancer. Dr. Daneshmand started by emphasizing that unfortunately, up to 50% of patients after radical cystectomy experience disease recurrence within five years of surgery. Furthermore, there are no currently available tests to determine which patients will have residual disease or be at risk of relapse. There are several options for liquid biopsies in urothelial carcinoma of the bladder and upper tract urothelial carcinoma as highlighted in the following figure:

SIU 2021: EAU Lecture: Co-Morbidity Tailored Treatment of Prostate Cancer 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a plenary session with the EAU lecture provided by Dr. Arnulf Stenzl discussing comorbidity tailored treatment of prostate cancer. Dr. Stenzl started his presentation by highlighting that the EAU 22 meeting will be held, in person, in Amsterdam from March 18-21, 2022, with four full days of scientific program and exhibition, 1,200+ speakers, 1,700+ posters and video abstracts, and live surgeries. With regards to prostate cancer and comorbidity, there are three important ‘Ps’ we should remember:

SIU 2021: State-of-the-Art Lecture: Testicular Cancer (New Markers, Changing Face of Testicular Cancer) 

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a plenary session with a State-of-the-Art lecture by Dr. Sia Daneshmand discussing new markers and the changing face of testicular cancer. Dr. Daneshmand started by highlighting that there are several challenges in testicular cancer, with several potential solutions:

SIU 2021: The Role of PSMA PET in mCRPC and PSMA-Radioligand Therapy

(UroToday.com) In the second Hot Topics session of the 2021 SIU Annual Congress focused on the role of prostate specific membrane antigen (PSMA) and theranostics in prostate cancer, Dr. Fleshner closed the session discussing the role of PSMA-PET imaging in metastatic castration-resistant prostate cancer (mCRPC) and PSMA-radioligand therapy (RLT).

SIU 2021: Role of Targeted Salvage Surgery in Biochemical Recurrence

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a hot topics session on PSMA theranostics with a presentation by Dr. Tobias Maurer discussing the role of targeted salvage surgery in biochemical recurrence. Dr. Maurer started by highlighting from the EAU guidelines that salvage lymph node dissection is not a standard treatment, specifically that “high-level evidence for the oncological value of salvage lymph node dissection is still lacking.”

SIU 2021: Initial Staging with PSMA

(UroToday.com) In the second Hot Topics session of the Société Internationale D’Urologie (SIU) 2021 annual meeting focused on the role of prostate specific membrane antigen (PSMA) and theranostics in prostate cancer, Dr. Robert Reiter began with a presentation on the role of PSMA-based imaging as a diagnostic tool in the initial staging of patients with prostate cancer.

SIU 2021: Role of Targeted Salvage Radiation and Metastasis-Directed Therapy in Biochemical Recurrence (BCR)

(UroToday.com) In the second Hot Topics session of the Société Internationale D’Urologie (SIU) 2021 annual meeting focused on the role of prostate specific membrane antigen (PSMA) and theranostics in prostate cancer, Dr. Ugur Selek presented on the role of targeted salvage radiotherapy and metastasis-directed therapy in patients with biochemical recurrent disease.

SIU 2021: New Systemic Therapies in Advanced Renal Cell Carcinoma  

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on advanced kidney cancer with a presentation by Dr. Ozcan Yildiz discussing new systemic therapies in advanced RCC. Dr. Yildiz started by highlighting that in 2000, the survival of metastatic RCC was quite poor, with a median OS of 5 months for those with poor-risk disease, 14 months for intermediate-risk disease, and 30 months for favorable-risk disease. Since then, there has been an explosion of FDA approvals for drugs in this disease space as highlighted in the following timeline:

SIU 2021: Nephrectomy as Part of the Sequencing Options in Metastatic Renal Cell Carcinoma with Primary in Place

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on advanced kidney cancer with a presentation by Dr. Kevin Lu discussing nephrectomy as part of the sequencing options in metastatic renal cell carcinoma (RCC) with the primary in place. Dr. Lu notes that we are in a rapidly evolving treatment landscape for metastatic RCC, highlighted by new drugs, drug combinations, drug sequences, vaccinations, improving local management, and precision therapy. As follows is a timeline of the current therapeutics available for advanced RCC:

SIU 2021: What Trials Do We Need in Advanced Renal Cell Carcinoma to Improve Outcomes  

(UroToday.com) The Société Internationale D’Urologie (SIU) 2021 annual meeting included a master class on advanced kidney cancer with a presentation by Dr. Axel Bex discussing the trials we need in advanced renal cell carcinoma (RCC) to improve outcomes. Dr. Bex started his talk by highlighting the danger of radiological window dressing noting that there are two important clinical scenarios when discussing treatment and time after nephrectomy:

email news signup